BiotechTube

Sonrotoclax + Zanubrutinib + Placebo

Phase 3Recruiting
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Mantle Cell Lymphoma

Conditions

Mantle Cell Lymphoma, B Cell Lymphoma

Trial Timeline

Mar 5, 2025 → Mar 30, 2032

NCT ID
NCT06742996

About Sonrotoclax + Zanubrutinib + Placebo

Sonrotoclax + Zanubrutinib + Placebo is a phase 3 stage product being developed by BeOne Medicines for Mantle Cell Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06742996. Target conditions include Mantle Cell Lymphoma, B Cell Lymphoma.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT06742996Phase 3Recruiting

Competing Products

20 competing products in Mantle Cell Lymphoma

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + Brexucabtagene AutoleucelEli LillyPhase 2
52
Obinutuzumab + Glofitamab + PirtobrutinibEli LillyPhase 2
52
enzastaurinEli LillyPhase 2
52
AbemaciclibEli LillyPhase 2
52
Pirtobrutinib + Ibrutinib + Acalabrutinib + ZanubrutinibEli LillyPhase 3
77
Pirtobrutinib + Rituximab + VenetoclaxEli LillyPhase 2
52
Pirtobrutinib and rituximabEli LillyPhase 2
52
gemcitabine + mitoxantrone + rituximabEli LillyPhase 2
52
Rituximab 375 mg/m^2 + Cyclophosphamide 750 mg/m^2 + Doxorubicin 50 mg/m^2 + VELCADE 1.3 mg/m^2 + Prednisone 100 mg/m^2 + Vincristine 1.4 mg/m^2Johnson & JohnsonPhase 3
77
VenetoclaxAbbViePhase 2
52
Ibrutinib + VenetoclaxAbbViePhase 2
52
ABT-199 and Ibrutinib CombinationAbbViePhase 1
33
Venetoclax Oral Tablet [Venclexta]AbbViePhase 2
52
Acalabrutinib capsuleAstraZenecaApproved
85
Acalabrutinib in combination with BR + Acalabrutinib in combination with VRAstraZenecaPhase 1
33
Acalabrutinib + Venetoclax + ObinutuzumabAstraZenecaPhase 1/2
41
Acalabrutinib + R-CHOP standard of care + Acalabrutinib combination with Rituximab + Acalabrutinib monotherapyAstraZenecaPhase 2
52
Acalabrutinib + Venetoclax + RituximabAstraZenecaPhase 2
52
Acalabrutinib + RituximabAstraZenecaPhase 2
52
Acalabrutinib Treatment A + Acalabrutinib Treatment B + Acalabrutinib Treatment C + Acalabrutinib Treatment DAstraZenecaPhase 1
33

Other Products from BeOne Medicines

ZanubrutinibApproved
82
Tislelizumab + Pamiparib + Temozolomide + Sitravatinib + Ociperlimab + BAT1706 + Fruquintinib + BGB-15025 + Zanidatamab + BGB-A445 + Surzebiclimab + Lenvatinib + LBL-007Phase 3
74
Zanidatamab + Tislelizumab + Trastuzumab + Capecitabine + Oxaliplatin + Cisplatin + 5-FluorouracilPhase 3
74
Zanubrutinib + Bendamustine + Rituximab + VenetoclaxPhase 3
74
Tislelizumab + Placebo + Cisplatin + Gemcitabine Hydrochloride + CarboplatinPhase 3
74